6:39:36 AM PDT - Wednesday, August 17th, 2022

Braxia buys KetaMD to get into remote-delivered ketamine treatments  

By Editor - Wed Aug 03, 2:52 am

  • Comments Off on Braxia buys KetaMD to get into remote-delivered ketamine treatments

Braxia Scientific is a Toronto-based company that focuses on depression, suicidality and related mental health conditions. Today, the company announced it is buying KetaMD to extend its telehealth prowess and in particular to expand its tech-facilitated ketamine-based treatments from its current local market of Florida into the wider U.S. The deal is worth around $6 million, the company told TechCrunch. KetaMD’s telemedicine platform provides access to affordable at-home ketamine treatments for people suffering from anxiety, depression and related mental health conditions. The company’s treatments are medically supervised, guided virtually by registered nurses with mental health expertise, and backed by psychiatrists and depression researchers. KetaMD’s integration of ketamine and telemedicine is guided by best practices and treatment guidance. With the acquisition of KetaMD, Braxia provides a compelling and differentiated value proposition.

See the rest here:

Braxia buys KetaMD to get into remote-delivered ketamine treatments

  • Comments Off on Braxia buys KetaMD to get into remote-delivered ketamine treatments

Leave a Reply

Comments are closed on this post.